MARKET

VYGR

VYGR

Voyager Therapeutics Inc
NASDAQ
8.77
-0.17
-1.90%
After Hours: 8.50 -0.27 -3.08% 19:23 07/12 EDT
OPEN
9.07
PREV CLOSE
8.94
HIGH
9.45
LOW
8.69
VOLUME
559.62K
TURNOVER
0
52 WEEK HIGH
11.72
52 WEEK LOW
6.06
MARKET CAP
477.03M
P/E (TTM)
-48.3729
1D
5D
1M
3M
1Y
5Y
1D
Insider Sales At Voyager Therapeutics Landed A Good Price
President Alfred Sandrock made the biggest insider sale in the last year at Voyager Therapeutics, Inc. (NASDAQ:VYGR) The company has seen no insider purchases over the past year. Our data suggests the insider sale of shares was at a higher price than the current share price. VoyagerTherapeutics insiders own 1.1% of the company. But the company may not be the best stock to buy.
Simply Wall St · 1d ago
VOYAGER THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 4d ago
Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
Seeking Alpha · 4d ago
Surprising Analyst 12-Month Target For XBI
NASDAQ · 5d ago
Weekly Report: what happened at VYGR last week (0701-0705)?
Weekly Report · 6d ago
Weekly Report: what happened at VYGR last week (0624-0628)?
Weekly Report · 07/01 09:17
Weekly Report: what happened at VYGR last week (0617-0621)?
Weekly Report · 06/24 09:18
Weekly Report: what happened at VYGR last week (0610-0614)?
Weekly Report · 06/17 09:17
More
About VYGR
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

Webull offers Voyager Therapeutics Inc stock information, including NASDAQ: VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VYGR stock methods without spending real money on the virtual paper trading platform.